

SCIENTIFIC REPORTS

OPEN

Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels

Laura Bonfili¹, Valentina Cecarini¹, Sara Berardi¹, Silvia Scarpona¹, Jan S. Suchodolski², Cinzia Nasuti³, Dennis Fiorini⁴, Maria Chiara Boarelli⁴, Giacomo Rossi¹ & Anna Maria Eleuteri¹

Gut microbiota has a proven role in regulating multiple neuro-chemical pathways through the highly interconnected gut-brain axis. Oral bacteriotherapy thus has potential in the treatment of central nervous system-related pathologies, such as Alzheimer's disease (AD). Current AD treatments aim to prevent onset, delay progression and ameliorate symptoms. In this work, 3xTg-AD mice in the early stage of AD were treated with SLAB51 probiotic formulation, thereby affecting the composition of gut microbiota and its metabolites. This influenced plasma concentration of inflammatory cytokines and key metabolic hormones considered therapeutic targets in neurodegeneration. Treated mice showed partial restoration of two impaired neuronal proteolytic pathways (the ubiquitin proteasome system and autophagy). Their cognitive decline was decreased compared with controls, due to a reduction in brain damage and reduced accumulation of amyloid beta aggregates. Collectively, our results clearly prove that modulation of the microbiota induces positive effects on neuronal pathways that are able to slow down the progression of Alzheimer's disease.

Alzheimer's disease (AD) is a common, progressive, and irreversible neurodegeneration with a gradual loss of memory, judgment, and ability to function. Treating and managing AD patients is a severe burden, and there is an urgent need to discover and validate new therapeutic agents. Most cases of early-onset AD derive from a combination of genetic mutations in genes encoding amyloid precursor protein (APP) and presenilins 1 and 2 (PSEN1 and PSEN2). APP cleavage by β and γ secretase complexes leads to the formation of amyloid- β (A β) peptides that can aggregate and form amyloid plaques, mainly composed of the 42 amino acid peptide (A β_{1-42}), which is less abundant but more prone to aggregation than the A β_{1-40} peptide. Amyloid deposits and neurofibrillary tangles, comprising hyper phosphorylated tau protein, are the most important pathologic hallmarks of AD. A β deposition and clearance are finely regulated by the ubiquitin-proteasome system (UPS) and autophagy, which are tightly interrelated¹⁻⁴. Impairment of proteolysis, which is characteristic of AD neurons, favors the accumulation of detrimental A β oligomeric structures that further contribute to proteasome and autophagy alterations.

Recently, several authors have described a role for gut peptide hormones in AD. These hormones are responsible for energy homeostasis and food intake regulation and show effects on the central nervous system (CNS), modulating nervous functions like learning and memory⁵⁻⁷. Ghrelin is involved in glucose and lipid metabolisms, but also in higher brain functions such as learning and memory; it influences mitochondrial respiration and exerts neuroprotective effects, takes part in the aetiopathogenesis of neurodegenerative disorders, representing a link between metabolism and neurodegeneration⁸. Ghrelin and leptin act as neurotrophic factors protecting cells against toxicity induced by A β oligomers^{5,9}. Plasma leptin concentration is negatively correlated to A β levels due to its direct regulatory effect on γ -secretase¹⁰. In addition, animal models of AD treated with leptin showed a reduction in A β and phosphorylated tau levels^{11,12}. The age-related decline in plasma ghrelin concentration and

¹School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy. ²Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, USA. ³School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032, Camerino, (MC), Italy. ⁴Division of Chemistry, School of Science and Technology, University of Camerino, I-62032, Camerino, MC, Italy. Correspondence and requests for materials should be addressed to L.B. (email: laura.bonfili@unicam.it)

the impairment of the ghrelin signaling observed in AD patients is closely related to the compromised memory and learning processes¹³. The glucagon-like peptide 1 (GLP-1) protects cultured neurons from oxidative damage and formation of A β plaques, and controls synaptic plasticity in mice^{14,15}. The use of glucose-dependent insulinotropic polypeptide (GIP) analogs as neuroprotective agents is an emerging and promising strategy in the treatment of AD^{16,17}.

Currently, no definitive treatment exists for AD, and most approaches aim to preserve cognition and memory and to delay the loss of function. Recent studies have highlighted a role for the human microbiome in regulating multiple neuro-chemical pathways through the highly interconnected host-microbiome system, the so-called gut-brain axis^{18–20}. Oral bacteriotherapy is becoming an accepted practice for the prevention and treatment of allergies²¹, gastrointestinal infections²², inflammatory conditions^{23,24} and cancer²⁵. Beneficial effects of lactic acid bacteria and bifidobacteria in CNS-related diseases such as multiple sclerosis, cognitive deficits, and stress-derived pathologies, have been recently documented^{26–31}. Probiotic supplementation reverses cognitive impairment and ameliorates the spatial memory in diabetic rats³². It has recently been shown that the probiotic mixture VSL#3 modulates the expression of a number of genes in the brain cortex of aged rats, with positive consequences on inflammatory and neuronal processes³³. Moreover, bacterial byproducts such as short chain fatty acids (SCFAs) exert a number of neuromodulator effects and directly act on gastrointestinal cells stimulating the synthesis of hormones such as leptin and GLP-1^{34,35}.

In the present study, a novel formulation of lactic acid bacteria and bifidobacteria (SLAB51) was administered to a triple-transgenic mouse model of Alzheimer's disease, B6;129-*Psen1^{tm1Mpm}* Tg (APP^{Swe}, tauP301L)1Lfa/J (named 3xTg-AD), in order to investigate the potential beneficial effects on memory deficits, amyloid plaque deposition, and neuronal proteolysis impairment. To gain insight into the effects of microbiota on AD progression the modulation of the gut-brain axis upon administration of the probiotic mix was also investigated.

Methods

Experimental design. 8-week-old male 3xTg-AD mice (n = 64) were organized in two groups: a treated group (administered for 4 months with SLAB51 in water) and a control group (administered with water). Simultaneously, 64 coetaneous wild type (wt) mice were divided into wt control and wt treated groups. At 8, 12, 18 and 24 weeks of age, 15 animals per group were given the open field (OF) and novel object recognition (NOR) tests. Elevated plus maze and passive avoidance tasks were added for mice at 24 weeks of age. Mice were sacrificed for biochemical analyses at 12, 18 and 24 weeks of age. (Sample size for each group was 8). Eight additional AD mice and eight wt mice were sacrificed at 8-weeks of age representing time 0 for biochemical and immuno-histological analyses.

In a second experiment a new batch of both AD (n = 20) and wt (n = 20) animals has been treated with water (n = 10) or SLAB51 (n = 10) to perform the NOR test directly at 24 weeks of age. This second test was necessary to verify the hypothesis that 24-weeks-old mice could be saturated, and not motivated to explore any objects again, upon repeating the NOR for the fourth time.

Availability of data and material. The data that support the findings of this study are available from University of Camerino but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the University of Camerino.

Experimental Procedures

Reagents and chemicals. SLAB51 formulation was provided by Mendes Sa (Lugano, Switzerland). Substrates for assaying the chymotrypsin-like (ChT-L), trypsin-like (T-L), and peptidyl glutamyl-peptide hydrolyzing (PGPH) activities of the proteasomal complex were purchased from Sigma-Aldrich S.r.L. (Milano, Italy). The substrate Z-Gly-Pro-Ala-Leu-Ala-MCA to test the branched chain amino acids preferring (BrAAP) activity was obtained from Biomatik (Cambridge, Ontario). Aminopeptidase N (EC 3.4.11.2) for the coupled assay utilized to detect BrAAP activity³⁶ was purified from pig kidney as reported elsewhere³⁷. Cathepsin B and cathepsin L substrates (Z-Arg-Arg-AMC and Z-Phe-Arg-AFC.trifluoroacetate) were from Sigma-Aldrich S.r.L. (Milano, Italy). Membranes for western blotting analyses were purchased from Millipore (Milano, Italy). Proteins immobilized on films were detected with the enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech, Milano, Italy). p27 antibody was purchased from Calbiochem (EDM Millipore, Billerica, MA). All the other antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany). ELISA Kit for A β _{1–40} and A β _{1–42} peptide determination in brain homogenates were purchased from Invitrogen (Camarillo, CA). Proteases inhibitors tosyl phenylalanyl chloromethyl ketone (TPCK) and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF or Pefabloc) were from Sigma-Aldrich S.r.L. (Milano, Italy).

Animals. The triple-transgenic mouse model of AD, B6;129-*Psen1^{tm1Mpm}* Tg (APP^{Swe},tauP301L)1Lfa/J (named 3xTg-AD) and their respective wild types mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). 3xTg-AD mice were previously characterized and represent a reliable model of human AD patients. In this model, A β intracellular immunoreactivity can be detected in some brain regions as early as three to four months of age³⁸. Experiments were conducted using 8-week-old male mice (weight 15–25 g) in accordance with the guidelines laid down by the European Communities Council (86/609/ECC) for the care and use of laboratory animals. Mice were housed in plastic (Makrolon) cages (4 animals per cage) in a temperature controlled room (21 ± 5 °C) and 60% humidity on 12 h light/dark inverted cycle (light was switched on at 8:00 P.M.) and maintained on laboratory diet (Mucedola, Italy) with water ad libitum. All appropriate measures were taken to minimize pain and discomfort in experimental animals. Brains, livers, feces and urines were properly stored at –80 °C after sacrifice.

All procedures were in accordance with the guidelines laid down by the European Communities Council (86/609/ECC) for the care and use of laboratory animals under an approved protocol (EUFTP#261473) by Veterinary Health Dept. of the Italian Ministry of Health.

SLAB51 administration. Two groups of mice ($n = 32$ animals for each group) were treated for four months as follows: a 3xTg-AD group orally treated with vehicle (water), a 3xTg-AD group orally treated with SLAB51, a formulation made of nine live bacterial strains (*Streptococcus thermophilus*, bifidobacteria (*B. longum*, *B. breve*, *B. infantis*), lactobacilli (*L. acidophilus*, *L. plantarum*, *L. paracasei*, *L. delbrueckii subsp. bulgaricus*, *L. brevis*)). The dosage (200bn bacteria/Kg/day) was calculated by application of the body surface area principle³⁹. Fresh drinking solution was changed every day. The body weight was measured every 2 weeks before starting the treatment and then once a month to ensure adequate intake of the experimental food.

Behavioral assessments. All behavioural experiments were performed during the animal's dark phase, with testing performed from 8:00 to 15:00. Animals were handled for 3 days before testing in order to accustom them to the experimenter. The investigators were blinded to the groups' allocation during the tests.

The open field (OF) test was used to evaluate the locomotor activity of mice using automated locomotor activity boxes (Med Associates, VT 05478) as previously reported⁴⁰. Locomotor activity was recorded for 5 mins, starting 1 min after placing the animal in the test cage. Each mouse was automatically recorded by interruptions of orthogonal light beams (3.5 cm above the activity box floor), which were connected to automatic software (Activity Monitor, Med Associates). The behavioral parameters observed were ambulatory (number of horizontal episodes) and stereotype counts (number of grooming movements).

The novel-object recognition (NOR) test is used to evaluate recognition memory and it is based on the spontaneous tendency of rodents to spend more time exploring a novel object than a familiar one. Mice were challenged in the open-field arena explored on the day before during OF. Following a training period, the animal was removed from the environment for a delay period of 3 h and then it was returned to the arena, where one of the two identical objects had been replaced by a new, dissimilar novel object (test phase). The amount of time the rodent spends exploring each object in 10 mins provides a powerful measurement of memory integrity and attention.

Results were expressed as discrimination score (seconds spent with novel object – seconds spent with familiar object)/(total time spent with both objects). Lower score indicates memory impairment in this task. Objects were different for shape, color and texture at each time point⁴¹ and maintained throughout the study to obtain reproducible data. Preliminary experiments were done to select novel and familiar object pairs on the basis that each object in the pairs elicited the same amount of spontaneous investigation.

The passive avoidance test is a fear-motivated test used to assess memory function based on the association formed between an aversive stimulus such as a mild foot shock and a specific environmental context. The amygdala plays a pivotal role in passive avoidance learning.

Apparatus and procedures were previously described⁴². Briefly, during the training test, each mouse received an electric shock when it entered the dark compartment. In the retention test, passive defensive reactions, assessed in terms of the latent period of transfer from the light to the dark compartment, were tested 24 h and 7 days after foot shock. Higher latency value translates to better retention of memory from the foot shock given during the learning phase⁴³.

The elevated plus maze (EPM) is a test used to detect anxiety-related behavior in animals⁴⁴. The apparatus, a cross-shaped wooden elevated maze, consisted of two opposite open arms 30 cm $\times$ 5 cm, and two opposite arms enclosed by 20-cm-high walls with two open arms and two closed arms. The maze was elevated 50 cm from the floor and lit by dim light. The procedure is described in Nasuti *et al.*⁴⁵. Changes in the percentage of time spent and number of entries into the open arms indicate changes in anxiety-like behavior. A greater percentage of time spent and number of entries in open arms indicates less anxiety-like condition.

Microbiota analysis. An aliquot of 100 mg (wet weight) of each fecal sample DNA was extracted with a DNA isolation kit (MoBio Power soil, MoBio Laboratories, USA) following the manufacturer's instructions. The V4 region of the 16S rRNA gene was amplified with primers 515 F (5'-GTGCCAGCMGCCGCGGTAA-3') and 806 R (5'-GGACTACVSGGGTATCTAAT-3') at the MR DNA Laboratory (Shallowater, TX, USA) as previously described⁴⁶. The Nextera[®] DNA sample Preparation kit including sequencing adapters and sample specific barcodes was used to prepare a DNA library and sequenced at MR DNA on an Illumina MiSeq instrument.

The raw sequences obtained were analyzed using the software QIIME v.1.8. A total of 5,343,083 were obtained. Sequences were demultiplexed, low quality reads were filtered using default parameters, chimeras removed and sequences were then clustered into operational taxonomic units (OTUs) using an open-reference OTU picking protocol at the 97% sequencing identity level against the Greengenes⁴⁷ database. For further analysis, each was rarefied to an even sequencing depth of 24,800 sequences to adjust for uneven sequencing depth across all samples. Observed species richness, Chao 1, and Shannon indexes were determined using QIIME. The software PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) was used to make functional gene content predictions based on 16S rRNA gene data generated by all organisms found in the data and represented in the Greengenes phylogenetic tree of 16S rRNA gene sequences. Because most datasets did not meet the assumptions of normal distribution as assessed by the D'Agostino and Pearson normality test, non-parametric statistical tests were used. The Friedman test with Dunn's post hoc test for repeated measures ANOVA was performed to evaluate changes among all timepoints. The resulting p-values were adjusted for multiple comparisons using the Benjamini & Hochberg's False Discovery Rate (FDR), and an adjusted $p < 0.05$ was considered statistically significant. Data were analyzed using Prism software 5.0 (GraphPad Software, San Diego, CA) and JMP software (SAS Institute, Cary, NC, USA). Linear discriminant analysis effect size (LEfSe), freely

available online in the Galaxy workflow framework, was used to elucidate taxa and genes associated with treatments at the various time-points. Analysis of beta-diversity was performed using unweighted Unifrac distance metrics. Statistical significance of the resulting distance metric was tested by analysis of similarities (ANOSIM) using the QIIME software. Sequences were deposited in the SRA archive under the accession number: SRP064106. The software PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) was used to predict the functional gene content in the fecal microbiome based on the 16S rRNA genes found in the data and represented in the Greengenes phylogenetic tree of 16S rRNA gene sequences. PICRUSt was used online in the Galaxy workflow framework. Linear discriminant analysis effect size (LEfSe) was used to elucidate bacterial taxa (16S rRNA genes) and functional genes (PICRUSt) associated with healthy or diseased cats.

Short chain fatty acids (SCFAs) determination. Fecal content of acetic, propionic and butyric acid has been quantified by means of headspace solid-phase microextraction coupled to gas chromatography with flame ionization detection by using a polydimethylsiloxane/carboxen/divinyl benzene coated fiber, following the procedure by Fiorini *et al.*⁴⁸ Data are expressed as mean content (mmol/Kg) $\pm$ SD and were statistically analyzed using one-way analysis of variance, followed by the Tukey-Kramer method for post-hoc analysis. Different superscript letters (a, b) indicate significant variations at $P < 0.05$ in the table.

ELISA assay for ghrelin, leptin and GIP, GLP-1. Plasma hormone concentrations were measured through ELISA using plasma treated with protease inhibitors (Pefabloc and TPCK).

Briefly, the Rat/mouse Ghrelin Active ELISA kit is a sandwich ELISA based on the capture of ghrelin molecules (active form) in the plasma by anti-ghrelin IgG and the immobilization of the resulting complex to the wells of a microtiter plate coated by a pre-titrated amount of anchor antibodies. After the binding of a second biotinylated antibody to ghrelin and the wash away of unbound materials, followed by conjugation of horseradish peroxidase to the immobilized biotinylated antibodies, the quantification of immobilized antibody-enzyme conjugates is performed by monitoring horseradish peroxidase activities in the presence of the substrate 3,3',5,5'-tetra-methylbenzidine. The enzyme activity is measured spectrophotometrically by the increased absorbency at 450 nm, corrected from the absorbency at 590 nm, after acidification of formed products. Since the increase in absorbency is directly proportional to the amount of captured rat/mouse ghrelin (active form) in the unknown sample, the concentration of active ghrelin can be derived by interpolation from a reference curve generated in the same assay with reference standards of known concentrations of rat/mouse ghrelin.

Leptin and GIP were determined using sandwich ELISA kit based on anti-leptin and anti-GIP monoclonal antibodies respectively.

Similarly, the quantitative determination of mouse glucagon like peptide-1 was performed using a sandwich ELISA kit (CUSABIO Cat #CSB-E08118m). Antibody specific for GLP-1 was pre-coated onto a microplate. Standards and samples are pipetted into the wells and any GLP-1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for GLP-1 is added to the wells. After washing, avidin-conjugated horseradish peroxidase is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of GLP-1 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Cytokine analyses. The plasma levels of pro- and anti-inflammatory cytokines were measured through ELISA using the Mouse Inflammatory Cytokines & Chemokines Multi-Analyte ELISA Array Kit (QIAGEN, Italy). Samples and standards were prepared following the manufacturer's protocols. Each cytokine level was calculated based on its own standard curve and expressed as mean concentration (pg/ml) $\pm$ SE.

Congo red staining and immunohistochemistry analysis. Three 3 μ m-thick parasagittal sections from each animal ($n = 8$ per sub-group), at ~ 0.84 , 1.20, and 1.56 mm lateral from the midline⁴⁹, were prepared. Selected sections were deparaffinized and rehydrated according to standard protocols, and they were used for Congo red staining and for A β and FGF9 immunohistochemical detection. Hematoxylin and eosin counterstaining was used to provide morphological details.

In detail, A β peptides were immunodetected using a polyclonal antibody with specificity for the A β_{1-42} C-terminus (Millipore, CA). Briefly, for each time point (8, 12, 18, 24 weeks of age), brain slides from treated and untreated wt and AD mice ($n = 8$ per subgroup) were fixed in a 50:50 mixture of methanol and acetone for 5 min and incubated with the anti-A β_{1-42} antibody (1:50). The binding of the antibody was detected with the Elite kit (Vector Laboratories), and the immunoreaction was developed using diaminobenzidine chromogen (DAB, Vector).

For FGF9 detection, brain sections were incubated overnight with anti-FGF9 rabbit polyclonal antibody (aa50-99) IHC-plusTM (LSBio Catalog No. LS-B11953), diluted 1:50, cross reacting with mouse, human, bovine and other animal species. Non-specific binding was blocked by incubation of slides for 10 minutes with a protein-blocking agent (Protein-blocking agent, Dako, Carpinteria, CA, USA) before application of the primary antibody. Slides were incubated overnight in a moist chamber. The immunoreaction with streptavidin-immunoperoxidase (Streptavidin-immunoperoxidase, Black & Decker, Towson, MD, USA) was visualized with 3,3'-diaminobenzidine substrate (3,3'-diaminobenzidine substrate, Vector, Burlingame, UK). Tissues were counterstained with Mayer's hematoxylin. For negative immunohistochemical controls the primary antibodies were omitted. Sections of human and bovine brain, AD and BSE respectively affected, served as positive control tissues for A β_{1-42} and FGF9 cell staining. For scoring of Congo red, A β_{1-42} , and FGF9 positive cells, these cells were quantified in different area of the mouse brain, particularly select compartments of the CNS as hippocampal area. All cellular types were evaluated using a light microscope (Carl Zeiss, Jena, Germany), a 40x objective, a

10x eyepiece, and a square eyepiece graticule (10×10 squares, having a total area of $62,500 \mu\text{m}^2$). Ten appropriate fields were chosen for each compartment and arithmetic means were calculated for each brain region. Results were expressed as IHC positive cells per $62,500 \mu\text{m}^2$. For all parameters, cells on the margins of the tissue sections were not considered for evaluation to avoid inflation of positive cell numbers. Positive Congo red/ $A\beta_{1-42}$ /FGF9 cells, amyloid interstitial plaques, and other CNS areas, were quantified by using an image-analysis system consisting of a light microscope (Carl Zeiss, Jena, Germany) attached to a Javelin JE3462 high-resolution camera and a personal computer equipped with a Coreco-Oculus OC-TCX frame grabber and high-resolution monitor. Computerized color-image analysis was performed by using Image-Pro Plus software (Media Cybernetics). The entire cerebral cortex and hippocampus were separately sampled with the counting frame size $250 \mu\text{m} \times 250 \mu\text{m}$ for cortex and $100 \mu\text{m} \times 100 \mu\text{m}$ for hippocampus. The area of each section in all cross brain sections in every mouse was recorded, as was the total number of neurons determined by immunostaining as previously described. For each mouse, the total brain area was calculated as the sum of the areas of all fields in all brain cross sections on one slide. Congo red, $A\beta_{1-42}$, and FGF9 positive cells were counted per section, and stained cell densities were expressed as the number of cells per square millimeter of analyzed section area²⁴. The sum of the area of all amyloid plaques was divided by the total area of cerebral cortex or hippocampus to obtain the amyloid burden. The pathologist performing quantification of amyloid burden was blind to age, treatment type, and genotype of mice. The unbiased stereological based quantification of amyloid burden was performed on the basis of methodology suggested by Liu *et al.*⁵⁰.

Measurement of the cortex. For the thickness measurement of the cortex wall, serial sections, in the coronal plane, from rostral to caudal of each mouse cerebrum were made. Briefly, the brains were removed, placed in 10% buffered formalin, covered with aluminum foil, and refrigerated. Two-mm-thick sections were cut 4, 6, and 8 mm from the frontal pole, and sections were photographed within 24 h. To prevent distortion, brain slices were kept flat in the Petri dish overnight. After the sections had been photographed, they were routinely processed and paraffin embedded, then newly $3 \mu\text{m}$ sectioned and stained with hematoxylin and eosin (H&E) and newly photographed. The serial sections were sub-divided into frontal, parietal, temporal, and occipital regions of the brain in rostral to caudal direction. Qualitative and quantitative analyses of the wall of the cerebral hemisphere were carried out on every 20th section. For each sub-group, 5 sections were analyzed. In each of these coronal sections, brains were stained with H&E and the cortex thickness was measured. For the assessment of regional cortical atrophy the thicknesses of the wall and laminae was determined by thickness measurements on H&E-stained sections. The different zones were measured using a calibrated integrating graticule (0.01 mm) in a single eyepiece. The method of point counting was used to determine the relative volume proportion of the cerebral wall, meninges and ventricles. The same stratified selected sections were projected onto a screen using a Leitz demonstration microscope ($\times 2.5$). A grid with 300 points was superimposed on the image. The points falling on the cerebral wall, meninges, and ventricle were counted field-by-field to cover the entire left and right cerebral hemispheres.

Ventricular sizes evaluation in the brain sections. Equivalent sections of 3xTg-AD, and wild-type mice brains were chosen on the basis of common morphological landmarks⁴⁹. Images of stained tissues were converted into TIFF format using Adobe Photoshop Elements 2.0. The areas of the brain substance and ventricles were measured using NIH ImageJ 1.39 u. Two images from each individual mouse were considered.

TUNEL analysis. In brain sections, apoptotic index was highlighted through a TUNEL colorimetric staining (DeadEnd, Promega®) according to the manufacturer's instructions. For evaluation of the apoptotic rate, ten random fields of any chamber were examined under a dry- 40x objective. TUNEL-positive cells are characterized by a brownish-black nuclear stain. Lower-power digitized images were acquired with a light microscope (Carl Zeiss, Jena, Germany) attached to a Javelin JE3462 high-resolution camera and a personal computer equipped with a Coreco-Oculus OC-TCX frame grabber and high-resolution monitor, and cells count and quantification were performed as previously reported.

Preparation of brain extracts. Brain extracts were homogenized (1:5 weight/volume of buffer) in 50 mM Tris buffer, 150 mM KCl, 2 mM EDTA, pH 7.5. Homogenates were immediately centrifuged at $13,000 \times g$ for 20 min at 4°C and the supernatant was collected for enzymes activity assays and western blotting. A small part of this supernatant fraction was immediately supplemented with protease inhibitors for hormones determination by ELISA as described below. Protein content was determined by the Bradford method⁵¹ using bovine serum albumin (BSA) as standard.

Proteasome activity assays. Proteasome peptidase activities in brain homogenates (supernatant fraction) were determined using synthetic fluorogenic peptides: Suc-Leu-Leu-Val-Tyr-AMC was used for ChT-L activity, Z-Leu-Ser-Thr-Arg-AMC for T-L activity, Z-Leu-Leu-Glu-AMC for PGPH activity, and Z-Gly-Pro-Ala-Phe-Gly-pAB for BrAAP activity⁵². The incubation mixture contained brain homogenates ($15 \mu\text{g}$ total proteins), the proper substrate ($5 \mu\text{M}$ final concentration) and 50 mM Tris-HCl pH 8.0, up to a final volume of $100 \mu\text{L}$. Incubation was performed at 37°C for 60 min and the fluorescence of the hydrolyzed 7-amino-4-methyl-coumarin (AMC) and 4-aminobenzoic acid (pAB) was detected (AMC, $\lambda_{\text{exc}} = 365 \text{ nm}$, $\lambda_{\text{em}} = 449 \text{ nm}$; pAB, $\lambda_{\text{exc}} = 304 \text{ nm}$, $\lambda_{\text{em}} = 664 \text{ nm}$) on a SpectraMax Gemini XPS microplate reader. The 26S proteasome ChT-L activity was tested including in the reaction mix 10 mM MgCl_2 , 1 mM dithiothreitol, and 2 mM ATP.

Cathepsin B and L. Cathepsin B and L proteolytic activities were measured following the protocol described by Tchoupe *et al.*⁵³ using the fluorogenic peptides Z-Arg-Arg-AMC and Z-Phe-Arg-AFC, respectively, at a final concentration of $5 \mu\text{M}$. The mixture for cathepsin B, containing $7 \mu\text{g}$ of protein lysate, was pre-incubated in

100 mM phosphate buffer pH 6.0, 1 mM EDTA and 2 mM dithiothreitol for 5 min at 30 °C. Upon the addition of the substrate, the mixture was incubated for 15 min at 30 °C. The mixture for cathepsin L, containing 7 µg of protein lysate, was incubated in 100 mM sodium acetate buffer pH 5.5, 1 mM EDTA and 2 mM dithiothreitol for 5 min at 30 °C and, upon the addition of the substrate, the mixture was incubated for 15 min at 30 °C. The fluorescence of the hydrolyzed 7-amino-4-methyl-coumarin (AMC, $\lambda_{exc} = 365$ nm, $\lambda_{em} = 449$ nm) and 7-amino-4-trifluoromethylcoumarin (AFC, $\lambda_{exc} = 397$ nm, $\lambda_{em} = 500$ nm) was detected on a SpectraMax Gemini X PS microplate reader.

Western blotting analyses. Brain homogenates (supernatant fraction) were analyzed through western blotting assays with the aim to measure the following intracellular protein levels: amyloid oligomers, ubiquitinated proteins, p53, p27 and the autophagy related proteins Beclin-1, p62 and LC3-II. In detail, for each time point brain homogenates (20 µg total protein) were loaded on 12% SDS-PAGE (15% for LC3; 10% for ubiquitinated proteins and amyloid oligomers) and electroblotted onto PVDF membranes. Successively, upon incubation with specific antibodies, the immunoblot detections were carried out with Enhanced ChemiLuminescence western blotting analysis system (Amersham Pharmacia-Biotech). Molecular weight markers (6.5 to 205 kDa) were included in each gel. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to check equal protein loading. The bands were quantified by using a densitometric algorithm. Each Western Blot was scanned (16 bits greyscale) and the obtained digital data were processed through Image J (NIH)⁵⁴ to calculate the background mean value and its standard deviation. The background-free image was then obtained subtracting the background intensity mean value from the original digital data. The integrated densitometric value associated to each band was then calculated as the sum of the density values over all the pixels belonging to the considered band having a density value higher than the background standard deviation. The band densitometric value was then normalized to the relative GAPDH signal intensity. The ratios of band intensities were calculated within the same Western Blot. All the calculations were carried out using the Matlab environment (The MathWorks Inc., MA, USA)⁵⁵.

ELISA assay for A β levels determination. Brain homogenates (supernatant fraction) promptly supplemented with protease inhibitors (Pefabloc and TPCK) were used to measure A β_{1-40} and A β_{1-42} levels using enzyme-linked immunosorbent assay NOVEX[®] ELISA kits (Invitrogen,). Based on preliminary tests, samples were diluted at 1:5 with diluent buffer provided by the kit. Assays were performed according to the manufacturer's directions.

Statistical analysis. Results of behavioral tests were expressed as mean $\pm$ S.E. In particular, the EPM was analyzed by mean of Student's t test. For the OP, NOR and passive avoidance, a two-way ANOVA with one factor within (time) and one factor between (treatment) was employed and appropriate post-hoc analysis was carried out using the Newman-Keuls test. Biochemical and IHC data are expressed as mean values $\pm$ S.E. Statistical analysis was performed with one way ANOVA, followed by the Bonferroni test using Sigma-stat 3.1 software (SPSS, Chicago, IL, USA). P-Values $p < 0.05$ were considered to be significant.

Results

Administration of SLAB51 counteracts cognitive decline and brain damage in AD mice. The effect of the probiotic on the consolidation process of memories in AD mice was assessed through the novel object recognition (NOR) and the passive avoidance tests, which have been used as cognitive probes for detecting hippocampus and amygdala functions, respectively.

In a first experiment, the AD mice were submitted to the NOR test at all time points (weeks 8, 12, 18 and 24) and differences between treated and control mice were observed ($F[1,28] = 6.8$, $p < 0.05$) as shown in Fig. 1, panel A. In particular, AD mice treated with the probiotic showed better “discrimination index” than untreated animals at 18 weeks of age, suggesting the beneficial effect of SLAB51 after 10 weeks of treatment. However, we could not see differences between 24-week-old treated and untreated mice. It is likely that mice may be not motivated to explore any objects again, regardless of whether they are familiar or novel. Indeed, compared to 18-week-old mice (25 s and 19 s for treated and untreated mice, respectively), the 24-week-old ones spent significantly less total time exploring both objects during the test phase (16.8 s and 9.6 s for treated and untreated mice, respectively). To verify this hypothesis, a second group of AD and wt mice were submitted to the NOR test at only two time points (weeks 8 and 24). Here, we could appreciate differences between treated and untreated AD mice when they were 24 weeks old ($F[3,40] = 2.95$, $p > 0.05$) as shown in Fig. 1, panel B. In particular, treated AD mice showed an improvement in cognitive performance compared to age-matched untreated AD mice, demonstrating a sustained beneficial effect of SLAB51 until 24 weeks of age. No significant differences were observed between treated wt mice and age-matched untreated wt mice.

In the first experiment, 24-week-old treated and untreated AD mice underwent the passive avoidance test. Statistical analysis computed on passive avoidance behavior of AD mice showed no significant differences in the test performed at 24 h and 7 days ($F[1,27] = 0.55$, $p > 0.05$) after the training test, whereas a significant effect of time ($F[2,54] = 117.84$, $p < 0.05$) was observed (data not shown). However, higher entry latencies near the cut-off value (300 s), measured in the retention test, demonstrated that AD mice were able to memorize the punishment and to perform the inhibitory avoidance, indicating that triple mutation did not impair amygdala function.

24-week-old treated and untreated AD mice, from the first experiment, were evaluated in the elevated plus maze (EPM) to analyze their anxiety-like behavior. Statistical tests computed on the % open arm entries ($df = 28$, $t = 0.30$, $p > 0.05$) and on the % time spent in the open arms ($df = 28$, $t = -1.08$, $p > 0.05$) revealed no significant between-group differences, reflecting the same level of anxiety-like responses in treated and untreated age-matched AD mice (Fig. 1, panel C).




Figure 1. SLAB51 ameliorates behavioral performance and reduces brain damage in AD mice. *Novel Object Recognition (NOR) test* (first experiment): 15 mice/sub-group were allowed to explore an identical pair of objects, and after 3 hours, they are presented with the familiar object and a novel object. The discrimination scores for 8, 12, 18, and 24-week-old AD mice are reported in panel A. *NOR test* (second experiment) performed for the first time on treated and untreated 24-week-old mice (groups' size = 10), panel B. Panel C: *Elevated plus maze test*. % open arm entries and % time spent in the open arms by untreated and treated AD mice at 24 weeks of age (first experiment, groups' size = 15). Data points marked with an asterisk are statistically significant compared to their respective non-treated control mice (* $p < 0.05$). Panel D Immunodetection of FGF9 protein in brain slides of 24-weeks old untreated and treated wt and AD mice (8 animals per group) from the first experiment. Results are reported as number of cells immunohistochemically positive for FGF9 per field $\pm$ ES (#statistically significant with respect to the corresponding untreated mice $p < 0.05$). For each histological section 5 randomly selected field were analyzed at 40xHPFs. Representative images of immunohistochemical staining are reported. Panel E: Brain weights expressed in grams $\pm$ ES of both treated and untreated wt and AD mice over time (groups' size is 8). Panel F: Measurement of the cortex thickness (mm) and ventricular sizes evaluation (mm³) in the brain sections of control and SLAB51 treated AD mice at 8, 12, 18 and 24 weeks of age. Data are reported as mean values $\pm$ ES (*statistically significant with respect to 8 weeks-old untreated mice $p < 0.05$; #statistically significant with respect to the corresponding untreated mice $p < 0.05$). Consecutive brain slides of treated and untreated 24 weeks-old AD mice are shown.

Weeks	8	12	18	24
Ambulatory counts				
AD control	571 ± 52.82	340 ± 55.16	384 ± 10.48	297 ± 8.53
AD + SLAB51	556 ± 80.92	367 ± 49.19	351 ± 14.55	298 ± 15.31
Stereotypic counts				
AD control	416 ± 12.60	378 ± 18.69	350 ± 13.60	313 ± 20.58
AD + SLAB51	410 ± 13.93	343 ± 21.83	325 ± 20.67	302 ± 19.47

Table 1. SLAB51 effect on locomotor activities. *Open Field test*. Locomotor activities were registered after 5 mins. Ambulatory and stereotypic counts are expressed as means ± SEM. Group sizes: AD control (n = 15), AD + SLAB51 (n = 15). (p > 0.05).

To verify that the beneficial effects of SLAB51 on attenuating cognitive impairment were not linked to an increased locomotor activity, AD mice (from the first experiment) were evaluated in an open field (OF) test at each time point (weeks 8, 12, 18 and 24). Two-way ANOVA revealed no differences in locomotor activity between treated and control AD groups (ambulatory counts: $F[1,28] = 0.116$, $p > 0.05$; stereotypic counts: $F[1,28] = 1.95$, $p > 0.05$) as shown in Table 1. These data suggested that SLAB51 treatment did not influence the locomotor activity of AD mice. Together, these findings rule out the possibility that, in the NOR, the different response between treated and control AD mice could depend upon differences in locomotor activity.

These results are consistent with the expression levels of FGF9 in the hippocampal areas of 24 week-old mice (4 months of treatment), as reported in Fig. 1, panel D. Based on published data indicating that specific growth factor transcripts are altered in depressed, stressed, and AD-affected brains^{56–58}, we selectively examined FGF9 differential expression in AD and wt mice. Results indicate a significant difference in FGF9 expression between treated and untreated AD mice, and a similar level and pattern of expression between treated AD and control wt mice. In fact, hippocampal FGF9 expression was consistently increased in untreated AD mice compared to treated AD and control wt mice. Thus, these analyses confirmed the alteration of FGF9 in depressive disorders, and show also its up-regulation in the altered hippocampus of AD-affected mice. Few studies have previously demonstrated the increased FGF9 expression in the frontal cortices⁵⁶ and locus coeruleus⁵⁷ in patients with major depression. Moreover, so far no data are available on the role of FGF9 in the hippocampus during AD or its role in the regulation of emotionality. Thus, our results could be helpful in elucidating the potential role of the hippocampal FGF9 in conditioning emotions and behavioral performances in AD.

The body weight of mice was controlled during the entire period of treatment and no differences were obtained between control and AD animals, indicating that the mixture was well tolerated. Interestingly, the brain weight of SLAB51-treated mice showed no changes, whereas in control animals a significant decrease over time was observed (Fig. 1, panel E).

Regarding brains morphology, it was immediately apparent that lateral ventricles were enlarged in 3 × Tg-AD untreated mice compared with SLAB51 treated animals (Fig. 1, panel F). In some areas of the brain, notable differences in the cortex thickness were observed between treated and untreated AD mice. Differences in thickness of the cerebral cortex were also minimal at t0 (8 weeks-old) and t1 (12 weeks-old), though the ventricular zone appeared slightly enlarged in untreated AD mice. Starting from t2 (18 weeks-old), the difference in cortical thickness became more pronounced between the two groups (Fig. 1, panel F) in particular in the hippocampal area (bregma −2.18 mm), at level of interventricular foramen (bregma −0.22 mm), and lateral ventricle at the point of alignment with the anterior arm of corpus callosum (bregma 0.62 mm). These data suggest the beneficial effect of SLAB51 in counteracting the decline of cortical thickness and the ventricular dilatation that are typical damages in AD brains.

SLAB51 modifies intestinal microbiota. PCoA plots of unweighted Unifrac distances revealed significant differences in microbiota structure between the wt and 3xTg-AD mice at all time points, but no significant differences were observed in species richness between wt and AD mice (Fig. 2). Considering untreated mice, lower concentrations of *Tenericutes*, *Cyanobacteria*, *Anaeroplasmatales*, and *Anaerostipes* were present in AD mice with respect to wt mice, with *Anaerostipes* playing an important role in gut health for the ability to produce butyric acid⁵⁹ (Supplemental Table S1). Furthermore, the microbiota structure underwent more changes over the various time points in the 3xTg-AD, as the distances in the PCoA plots were larger, while the distances between the weeks clustered closer together in the wt mice. Moreover, treatment with SLAB51 induced larger changes in AD mice compared to wt mice. However, after adjustment for multiple comparisons, only a few bacterial taxa were found to be significantly different when either group of mice were or were not treated with SLAB51 (Supplemental Tables S2 and S3). Overall, similar changes in specific taxa were observed between the animal groups, and most notably, an increase in *Bifidobacterium spp.* and a reduction in *Campylobacteriales* (i.e., *Helicobacteriaceae*; $p = 0.04$) was observed in both mouse groups when treated with SLAB51. The predicted functional bacterial metagenome content using PICRUSt revealed different effects of SLAB51 between wt and 3xTg-AD mice. While 14 pathways were increased (LDA score >4.0) due to SLAB51 in the 3xTg-AD mice, only one pathway was increased in wt mice (Table 2). SLAB51 induced several metabolic pathways in the 3xTg-AD mice, including DNA repair, pyrimidine metabolism, transcription machinery, energy metabolism, and glycolysis-gluconeogenesis.

Additionally, the fecal content of SCFAs was evaluated considering that these bacterial byproducts are known to act on the brain and that may mediate the effect on AD pathology. Interestingly, Table 3 shows that acetic,




Figure 2. Microbiota analysis. PCoA plots based on unweighted Unifrac distances and rarefaction curves are presented. The microbiota was analyzed using 16S rRNA gene sequencing. PCoA plots based on unweighted Unifrac distances reveal separation between the microbiota of wt and AD mice at all time points, indicating that the affected mice have different microbiota structure compared to wt mice. No significant differences were found in alpha diversity indices, revealing no difference in species richness. The progression over time from week 8 to week 24 was more pronounced in the AD mice compared to the wt mice. Also, treatment with SLAB51 induced larger changes in AD mice compared to wt mice, but no differences in species richness (t0 = 8 weeks; t1 = 12 weeks; t2 = 18 weeks; t3 = 24 weeks).

propionic and butyric acids significantly increased in AD mice upon SLAB51 treatment. Considering that the composition of gut microbiota and its metabolites can influence the inflammatory signaling, a panel of pro- and anti-inflammatory cytokines has been evaluated in the plasma of both wt and AD mice administered with water or SLAB51. Upon SLAB51 administration reduced plasma concentrations of pro-inflammatory cytokines have been observed in AD mice (Fig. 3), confirming that the modified microbiota produced anti-inflammatory effects. In detail, higher plasma concentrations of pro-inflammatory cytokines such as IL1 α , IL1 β , IL2, IL12, IL17, IFN γ , and TNF α were observed in untreated AD mice with respect to wt counterpart. Interestingly, upon SLAB51 treatment a significant decrease of IL1 α , IL1 β , IL2, IL12, IFN γ , and TNF α occurred. Moreover IL4, IL6, G-CSF, and GM-CSF, are less concentrated in the plasma of untreated AD mice with respect to wt mice. The probiotic treatment resulted in an increase of these cytokines that can down-regulate inflammatory response⁶⁰. Collectively, these data are in agreement with the enriched gut content of the recognized anti-inflammatory SCFAs in AD mice upon probiotics supplementation.

Increased gut hormone concentration with SLAB51 treatment. We measured the plasma concentration of the gut peptide hormones ghrelin, leptin, GLP-1 and GIP because of their neuroprotective effects and potential as therapeutic targets. No changes in hormone plasma levels were observed in treated wt mice compared to the respective controls. An age-dependent decrease of the levels of all the tested hormones was observed in untreated AD mice. Interestingly, treatment with the probiotic formulation specifically increased the plasma concentration of these hormones. Results indicate significantly increased levels of ghrelin and GIP in 18- and 24-week-old treated AD mice compared to their respective controls. The level of leptin upon SLAB51 administration increased in treated 24-week-old AD mice compared to untreated animals. Treatment with SLAB51 induced an increase in GLP-1 plasma concentration by 12 weeks of age (Fig. 4).

SLAB51 decreased amyloid load in AD mice brain. To assess if SLAB51 treatment had effects on brain A β load, we first measured the levels of A β ₁₋₄₀ and A β ₁₋₄₂ peptides. As expected, amyloid peptides did not increase in wild type mice (data not shown). Interestingly, A β ₁₋₄₂ load was significantly reduced in 12-week-old AD mice treated with SLAB51 compared to controls. No significant effect on A β ₁₋₄₀ levels was observed (Fig. 5, panel A). We then evaluated the accumulation of amyloid oligomers through western blotting and found a considerable

KEGG orthologs	LDA score	Group
Two-component system	4.20	3xTg-AD not treated
Bacterial motility proteins	4.13	3xTg-AD not treated
Secretion system	4.10	3xTg-AD not treated
General function prediction only	4.55	3xTg-AD treated SLAB51
DNA repair and recombination proteins	4.47	3xTg-AD treated SLAB51
Pyrimidine metabolism	4.31	3xTg-AD treated SLAB51
Peptidases	4.30	3xTg-AD treated SLAB51
Chromosome	4.21	3xTg-AD treated SLAB51
Amino sugar and nucleotide sugar metabolism	4.17	3xTg-AD treated SLAB51
Ribosome biogenesis	4.15	3xTg-AD treated SLAB51
Methane metabolism	4.14	3xTg-AD treated SLAB51
DNA replication proteins	4.13	3xTg-AD treated SLAB51
Alanine aspartate and glutamate metabolism	4.06	3xTg-AD treated SLAB51
Energy metabolism	4.04	3xTg-AD treated SLAB51
Glycolysis-gluconeogenesis	4.02	3xTg-AD treated SLAB51
Transcription machinery	4.01	3xTg-AD treated SLAB51
Homologous recombination	4.01	3xTg-AD treated SLAB51
Function unknown	4.13	wt not treated
Other ion-coupled transporters	4.07	wt treated SLAB51

Table 2. Effects of SLAB51 on KEGG orthologs in 24 weeks old wt and 3xTg-AD mice.

	Acetic acid (mmol/Kg)	Propionic acid	Butyric acid	Total SCFA
AD control	26.64 ^a ± 5.66	8.53 ^a ± 2.91	4.15 ^a ± 4.15	39.31 ^a ± 11.61
AD + SLAB51	42.62 ^b ± 2.23	13.65 ^b ± 3.30	15.52 ^b ± 7.81	71.79 ^b ± 12.03

Table 3. Short chain fatty acids (SCFA) fecal content (mmol/Kg) ± standard deviation in 24 weeks old 3xTgAD mice. Different letters within the same column indicate significant differences ($P < 0.05$, one-way analysis of variance and Tukey's test for pairwise comparison).

reduction of these toxic structures in treated AD mice, at both 18 weeks and 24 weeks of age, compared to controls (Fig. 5, panel B). Congo red staining of brain A β plaques evidenced a significant reduction of extracellular amyloid deposits, associated with substantially lower levels of staining of somata and processes of hippocampal pyramidal cells from Ammon's horn, and in granule cells from dentate gyrus, especially in sections of AD mice treated with the SLAB51 mixture (Fig. 5, panel C). Regarding the effects of SLAB51 on wt animals, no significant changes in the amount of amyloid peptides were observed, as also demonstrated histologically in Congo red stained sections (Fig. 5, panel C). Moreover, immunoreactivity towards A β_{1-42} peptide was progressively seen in somata and processes of hippocampal pyramidal cells and cortical neurons of untreated AD mice. Lower amounts of A β_{1-42} deposits were immunodetected in SLAB51 treated AD mice (Fig. 5, panel D).

Effect of SLAB51 mixture on proteasomal and autophagic proteolytic activity. Brain homogenates were analyzed through enzymatic assays and western blotting analyses in order to monitor the functionality and expression levels of components of the proteolytic pathways UPS and autophagy. In wt mice, SLAB51 did not modify proteasome functionality at any time point. A different result was obtained when analyzing AD mice. In fact, proteasome activity decreased in 3xTg-AD control mice, whereas AD mice treated with SLAB51 showed partially restored activity. In particular, 18- and 24-week-old treated AD mice showed increased ChT-L, T-L, and PGPH activity compared to age-matched untreated controls. A re-establishment of BrAAP activity was already evident at 12 weeks of age (Fig. 6). A similar pattern was obtained measuring the ChT-L activity of the 26S proteasome, the complex in charge of the removal of ubiquitinated proteins, where a significant recovery of activity was evident in treated AD mice at each time point (Fig. 6). To confirm these data, we performed western blotting assays to detect p27, p53 and ubiquitinated proteins, known substrates of the proteasome and markers of its functionality. At the analyzed time points, treated and untreated wt mice showed no significant differences in the expression levels of these proteins (Fig. 7). As expected, AD mice displayed a considerable accumulation of the analyzed substrates due to the strong proteasome impairment typical of neurodegeneration⁶¹. Figure 6 indicates that in AD mice, SLAB51 treatment induced a decrease in the levels of these markers in agreement with the data from the activity assays. The reduction in the buildup of ubiquitinated proteins induced by SLAB51 was significant in 18-week-old mice, whereas the effects on p27 and p53 were already evident in 12-week-old mice. The accumulation of these substrates, in particular p53, in treated and control AD mice, correlates with the significantly different apoptotic index at the neuronal level, especially in the granule cells layer from the hippocampal




Figure 3. Inflammatory cytokines. ELISA of inflammatory cytokines measured in the plasma of 24 week-old wt and AD mice untreated or treated with SLAB51. Analytes concentrations are expressed as mean $\pm$ SE. Data points marked with an asterisk are statistically significant compared to their respective untreated mice (* $p < 0.05$).

area of dentate gyrus (Fig. 8), and also in the pyramidal cells layer from Ammon's horn of the hippocampal area. No statistically significant differences in apoptotic levels were observed in 24-week-old treated AD mice and in treated or control wt mice. The considerable accumulation of p53 due to the strong proteasome impairment observed in untreated AD mice confirms the ability of this substrate to trigger the apoptotic pathway; as expected, treatment with the probiotic mixture induced a considerable decrease in apoptotic activity, regulating the levels of proteasome substrates.

Among the lysosomal enzymes, cathepsin B and cathepsin L were evaluated. Cathepsin B (CatB) is a cysteine protease associated with amyloid plaques and suggested to reduce A β levels⁶². A decrease in Cathepsin B activity was observed in 18- and 24-week-old treated mice compared with controls. Conversely, SLAB51 was able to restore cathepsin L (CatL) activity in 18- and 24-week-old mice compared with controls (Fig. 9). This finding is of particular interest considering the ability of the enzyme to increase α -secretase activity, thereby suppressing A β levels⁶³. Exposure to SLAB51 did not change the activity of either enzyme in wt mice.

The levels of the autophagy-related proteins beclin-1, LC3-II, and p62 were detected through western blotting assays. Beclin-1 plays a key role in autophagy, being involved in the enrolment of membranes to form autophagosomes⁶⁴. LC3-II is tightly bound to the autophagosomal membranes and is an established autophagic marker⁶⁵. p62 binds to both LC3-II and ubiquitin, and is finally degraded in autophagolysosomes. Therefore, p62 levels inversely correlate with autophagic activity⁶⁶. Our data show that in AD mice, treatment with SLAB51 increased the levels of beclin-1 and LC3-II and decreased the amounts of p62, suggesting an activation of the autophagic flux (Fig. 9).

Discussion

AD is a progressive neurodegenerative disorder, with age the major risk factor. AD patients are characterized by cognitive impairment and dementia, the accumulation of neurofibrillary tangles and A β senile plaques, neurite and brain cell atrophy, and increased oxidative stress and pro-inflammatory signals^{67, 68}. Interestingly, the role of microbes in both aging and the onset and progression of AD has been emerging in recent years^{26, 69}. In this regard, studies conducted on animal models showed that modifications of gut microbiota induced by oral bacteriotherapy reflect changes in genes involved in inflammatory and neuronal plasticity processes, with a positive impact on neuronal function^{33, 70}.

In the present work, we assessed the potential beneficial effects of modulating gut microbiota composition by a four-month treatment with SLAB51 (a mixture of lactic acid bacteria and bifidobacteria) in a triple transgenic mouse model of AD, 3x-Tg AD mice³⁸, in the early stages of the disease.

Significant differences in microbiota structure were observed at all time points between the wt and the 3xTg-AD mice, and these differences were independent of treatment. However, treatment with SLAB51 induced larger shifts in microbial communities in the 3xTg-AD mice, as evidenced by more pronounced changes in Unifrac distances. Interestingly, this did not lead to obvious differences in abundances of specific bacterial taxa, suggesting more gradual shifts across the entire microbiota. However, the functional content as predicted by PICRUSt was associated with more changes due to SLAB51 in AD mice, as more pathways were increased due to treatment. Of interest is that SLAB51 induced several metabolic pathways associated with energy metabolism, amino acid metabolism, and nucleotide metabolism.

The increase in *Bifidobacterium* spp. and the reduction in *Campylobacteriales* observed in AD mice upon administration with SLAB51 is important for the role of these bacteria in inflammatory pathways. In fact, *Bifidobacterium* strains possess anti-inflammatory properties principally attributed to small heat-stable, non-lipophilic compounds resistant to protease and nuclease treatments⁷¹. Moreover, certain species of genus




Figure 4. Plasma concentrations of gut hormones. Hormones were determined in the plasma of treated and control wt and AD mice. Results are expressed as percentage with respect to 8 week-old untreated mice. Data points marked with an asterisk are statistically significant compared to 8 week-old untreated control mice (* $p < 0.05$). Data points marked with hash are statistically significant compared to their respective control mice in the same time point ($^{\#}p < 0.05$).

Bifidobacterium could negatively modulate mRNA levels of pro-inflammatory cytokines produced from LPS-stimulated macrophages⁷². Instead, immune-stimulatory effects of *Campylobacter jejuni* and *Campylobacter coli* have been observed on peripheral blood mononuclear cells⁷³. Additionally, *in vivo* studies demonstrated that the purified lipooligosaccharide of *Campylobacter jejuni* increased the expression of pro-inflammatory cytokines in chickens⁷⁴. Upon SLAB51 administration reduced plasma concentrations of pro-inflammatory cytokines have been observed in AD mice (Fig. 3), confirming that modification of microbiota produced anti-inflammatory effects in probiotic administered subjects. Interestingly treated AD mice possess higher levels of G-CSF that is a modulator of systemic immune responses by inhibiting pro-inflammatory cytokines and has been demonstrated to decrease β -amyloid deposition and to reverse cognitive impairment in an AD mice model⁶⁰.




Figure 5. Aβ load. Panel A: Aβ₁₋₄₀ and Aβ₁₋₄₂ levels expressed as pg/ml determined by ELISA in the brains of AD mice treated or not with SLAB51 (n = 8). Panel B: Expression levels of amyloid oligomers detected by western blot. The densitometry from five separate blots and a representative immunoblot are reported. Equal protein loading was verified by using an anti-GAPDH antibody. The detection was executed by ECL. Data points marked with an asterisk are statistically significant compared to 8 weeks-old controls (*p < 0.05). Data points marked with hash are statistically significant compared to their respective control mice in the same time point (#p < 0.05). Uncropped gels are reported in Supplemental Figure 1. Panel C: Congo red staining of extra- and intra-cellular amyloid deposits in 24-week-old wt and AD mice administered with water or SLAB51 (groups' size is 8). Specific Congo red staining was progressively seen in somata and processes of hippocampal Ammon's horn pyramidal cells (insert), especially in untreated AD mice. Strong extracellular deposits demonstrate the formation of amyloid plaques, also visualized by immunostaining. (Congo red stain, with Meyer's hematoxylin nuclear counterstain. Coronal sections, Bar = 400 μm; dentate gyrus magnification, Bar = 200 μm; insert, Bar = 50 μm). Data are presented as positive cells/field and are representative of 5 histological section for each brain (n = 8 per sub-group). Data points marked with a hash are statistically significant compared to their respective water-treated mice (p < 0.05). Panel D: Aβ₁₋₄₂ IHC stain: wt and AD mice administered with water (control) or SLAB51. In both upper (low magnification) and lower (high magnification) groups of images, immunoreactivity towards Aβ₁₋₄₂ peptide (Aβ₁₋₄₂ C-terminus pAb, Millipore) was progressively seen in somata and processes of hippocampal pyramidal cells and cortical neurons of AD untreated mice. A strong extracellular reactivity, associated with Aβ plaque formation, can be observed in both treated and untreated AD mice (IHC stain, with Meyer's hematoxylin nuclear counterstain. Coronal sections, Bar = 400 μm; dentate gyrus magnification, Bar = 200 μm). The histogram shows the Aβ₁₋₄₂ positive cells/field. Data represent 5 histological section for each brain (n = 8). Data points marked with a hash are statistically significant compared to their respective water-treated mice (p < 0.05).




Figure 6. Effect of SLAB51 on proteasomal activity. Proteasome activity in SLAB51 treated and untreated wt (left) and AD (right) mice. The ChT-L, T-L, PGPH and BrAAP activities of the 20S proteasome and the ChT-L activity of the 26S proteasome were measured in brain homogenates as described in the Methods section. Results are expressed as fluorescence units (U. F.). Data points marked with an asterisk are statistically significant compared to untreated 8-week-old mice (* $p < 0.05$). Data points marked with a hash are statistically significant compared to their respective control mice in the same time point (* $p < 0.05$).




Figure 7. Effect of SLAB51 on proteasomal substrates. Detection of the levels of ubiquitinated proteins (panel A), p27 (panel B) and p53 (panel C) in SLAB51 treated and untreated wt and AD mice. The densitometric analyses obtained from five separate blots and representative immunoblots are shown. Equal protein loading was verified by using an anti-GAPDH antibody. The detection was executed by an ECL western blotting analysis system. Data points marked with an asterisk are statistically significant compared to 8-week-old control mice (* $p < 0.05$). Data points marked with a hash are statistically significant compared to their respective control mice at the same time point (# $p < 0.05$). Uncropped gels are reported in Supplemental Figure 1.

Behavioral tests highlight a positive effect of oral treatment with SLAB51 on behavioral performance in AD mice, suggesting the restoration of hippocampus functions, in agreement with published evidence supporting the idea that cognitive functions are affected by bacteria acting through the gut-brain axis. Some authors have demonstrated that certain strains of *Lactobacillus* and *Bifidobacterium* secrete essential neurotransmitters such as gamma-aminobutyric acid (GABA) and acetylcholine that mediate the positive impact of probiotics on behavior in neurological dysfunctions⁷⁵. Additionally, an impact on anxiety of *Campylobacter jejuni* infection has been previously reported in central nervous system disorders⁷⁶. In our study, the improved cognitive activity in treated AD mice did not correlate with different levels of anxiety. Interestingly, analysis of microbiota showed a reduced presence of *Campylobacteriales* in the treated AD group compared with the untreated AD group (Supplementary Table 2). This result is valuable also considering that a high prevalence of *Campylobacteriales* infections have been observed in AD patients and, after *Helicobacter pylori* eradication, cognitive and functional status parameters ameliorated⁷⁷.

Improvement of cognitive function is supported by increased plasma concentration of gut hormones such as ghrelin, leptin, GLP1 and GIP. Peptide hormones secreted in the gut play a role in modulating nervous functions like learning and memory. The time-dependent decrease of both ghrelin and leptin plasma concentrations in AD mice are in agreement with previously published data showing altered peripheral levels of these hormones in AD patients^{8,78}. Moreover, some authors previously demonstrated 3–4 months-old male 3xTg-AD mice exhibit significantly higher basal mineralocorticoids and glucocorticoids mRNA levels in the hippocampus and increased glucocorticoids but decreased corticotrophin releasing hormone mRNA levels in the paraventricular nucleus of the hypothalamus compared to male WT mice⁷⁹. Thus, the progressive decrease of circulating metabolic hormones concentration in untreated AD mice may be due to the unbalanced hypothalamic-pituitary-adrenal axis. In fact, these hormones are affected by several factors such as stress, and glucocorticoids levels⁸⁰. Interestingly, mice treated with the probiotic mixture showed higher plasma levels of such hormones, and this is important because ghrelin has been proven to counteract memory deficits and synaptic degeneration in AD animal models⁹, and leptin has been demonstrated to act as neurotrophic factor and to exert neuroprotective effects against




Figure 8. TUNEL detection of apoptotic neurons in hippocampal area of SLAB51 treated and untreated AD and wt mice. Apoptotic cells are characterized by black-brownish nuclear stain, as shown in the representative images. (TUNEL (DeadEnd, Promega®) reaction, with Meyer's hematoxylin nuclear counterstain. Bar = 200 μm.). The histogram shows the TUNEL positive cells/field. Data are representative of 5 histological section for each brain (n = 8 per sub-group). Data points marked with a hash are statistically significant compared to their respective water-treated mice (p < 0.05).

toxicity induced by Aβ oligomers *in vitro*^{5,6}. These data correlate with the decreased Aβ deposits in the brains of treated AD mice, and they are in good agreement with evidence showing that plasma leptin concentration is negatively associated to Aβ levels due to a direct regulatory effect on the γ-secretase-mediated amyloidogenic pathway¹⁰. The age-related decline of plasma ghrelin concentration and the impairment of ghrelin signaling observed in AD patients are closely related to the compromised memory and learning processes. Oral administration of SLAB51 enhanced GLP-1 and GIP plasma concentrations in AD mice, resulting in a neuroprotective effect of both incretins⁸¹. Again, GLP-1 has been shown to reduce Aβ load *in vivo* and in cultured neuronal cells¹⁴. Interestingly, following SLAB51 administration an increase of the bacterial metabolites SCFAs has been detected in feces of AD mice. Considering that bacterial by products such as SCFAs exert a number of neuromodulator effects and directly act on gastrointestinal cells stimulating the synthesis of hormones like leptin and GLP-1³⁴, our data contribute to define the link between gut microbiota modulation and metabolic hormones. Moreover, the enriched gut concentration of SCFAs, well recognized anti-inflammatory bioactive metabolites^{82,83} is encouraging also because of the number of evidences supporting SCFAs therapeutic potential in neurodegenerations⁸⁴. For example, histone deacetylase inhibitor 4-phenylbutyrate is responsible for restoring fear learning, counteracting intraneuronal Aβ deposition, and regulating dendritic spine density by exerting a chaperone-like activity and via the transcriptional activation of key proteins in synaptic plasticity and structural remodeling⁸⁵. Here we show that SLAB51 administration exerts multiple effects by modulating gut microbiota composition and causing metabolic changes, such as the increase of SCFAs able to directly act in the gut and in the brain, due to their ability to pass the blood brain barrier⁸⁶.




Figure 9. Autophagic markers. Panel A: Cathepsin B and cathepsin L activity in SLAB51 treated and untreated wt and AD mice. Results are expressed as fluorescence units. Data points marked with an asterisk are statistically significant compared to their respective untreated control mice (* $p < 0.05$). Panels B,C,D: levels of the autophagy-related proteins Beclin 1, p62 and LC3-II in SLAB51 treated and untreated wt and AD mice. Representative immunoblots and corresponding densitometric analyses obtained from five separate blots are shown. Equal protein loading was verified by using an anti-GAPDH antibody. The detection was executed by an ECL western blotting analysis system. Data points marked with an asterisk are statistically significant compared to 8-week-old control mice (* $p < 0.05$). Data points marked with a hash are statistically significant compared to their respective control mice at the same time point (# $p < 0.05$). Original membranes strips are reported in Supplemental Figure 1.

Innovatively, we show that probiotics counteracted the typical morphological alterations of AD, including the reduction in brain weight, the decline of cortical areas, and the general brain damage and shrinkage. Furthermore, SLAB51 contributed to a consistent reduction in the amount of cerebral A β , both in the form of peptides and oligomers. Consequently, a decreased number and size of amyloid plaques were observed upon treatment. Considering a recently published work in which *Lactobacillus helveticus* ameliorated APP metabolism in cell-based assays, favored memory in mice, and reduced A β_{1-40} serum concentration in rats⁸⁷, our findings prove a beneficial role for probiotic bacteria in AD subjects, identifying a synergistic effect obtained through the use of a successful formulation.

Exploring proteolytic pathways, normally impaired in AD, we evaluated the ability of the treatment to restore their functionality in neurons. Several papers have described dramatically impaired proteasome functionality in AD^{1,88}. For the first time, the probiotic mixture partially restored both 20S and 26S proteasomes activities. Enzymatic activities were confirmed through western blotting analyses investigating the levels of specific proteasomal substrates, such as ubiquitin conjugates, p27 and p53 proteins. All these proteins accumulated with proteasome inhibition, whereas their levels decreased upon SLAB51 treatment. In particular, as the treatment restores proteasome functionality, p53 levels diminished and a decrease in apoptotic levels was detected in granule cells from dentate gyrus of hippocampal areas, and in some pyramidal cells of the Ammon's horn of AD treated mice. An increase in p53 immunoreactivity has been previously observed in sporadic AD^{89,90}, especially in cortical neurons undergoing neurofibrillary degeneration⁹¹. The time-dependent p53 increase in untreated AD mice is also in agreement with a work demonstrating that p53 is upregulated approximately 2-fold in the superior temporal gyrus of Alzheimer's patients compared to healthy elderly control subjects⁹².

Moreover, SLAB51 administration triggered autophagy, as demonstrated by the decrease of cathepsin B activity and the increase of cathepsin L activity. These lysosomal enzymes are differently involved in AD development: the cysteine protease cathepsin B is associated with amyloid plaques in AD brains and has been suggested to be responsible for the increase in A β production. Conversely, cathepsin L activity increases α -secretase-mediated non-amyloidogenic pathway. Western blotting of autophagy markers confirmed that this pathway is activated in treated AD mice. Therefore another pioneering piece of evidence is that the SLAB51 probiotic formulation restored altered autophagy in AD. Collectively, biochemical analyses on proteolysis demonstrate that SLAB51 probiotic mixture significantly influences proteolysis, restoring impaired proteasome activities and consequently modulating the autophagic flux, confirming the crosstalk between the two pathways¹. We believe that SLAB51's positive effects on proteolysis are mediated by increased gut hormones. In fact, in a recent paper we demonstrated that ghrelin controls neural homeostasis through direct regulation of UPS and autophagy in AD neuronal cells⁹³.

Furthermore, it has been demonstrated that autophagy negatively regulates Wntless-related integration site (Wnt) signaling, which is involved in cell migration, apoptosis and differentiation of the CNS⁹⁴, and its targets, among them FGF9. Our results show that treatment with SLAB51 restores autophagy and modulates gut hormone production in AD mice. These results suggest that microbiota composition influences Wnt signaling and provide an explanation of the reduced expression of FGF9 in the CNS. Increased levels of FGF9 in the hippocampus of subjects with major depressive disorder have been observed. In rodent models of affective disorders, chronic social defeat stress increased anxiety, compromised social interaction, and decreased body weight, and was associated with increased hippocampal FGF9 expression⁹⁵. Accordingly, FGF-9 immunoreactivity has been detected in human hippocampal and cortical neurons, astrocytes, and dystrophic neurites of senile plaques, in hippocampal sections of AD patients⁹⁶. In this study an association between hippocampal FGF9 expression and severity of lesions related to AD in mice was observed. Therefore, reduced hippocampal expression of FGF9 in 24-week-old AD mice treated with SLAB51, comparable to wt mice FGF9 hippocampal expression, contributes to the improvement of behavioral performances.

Previous studies demonstrated that modifications to the microbiota modulate the expression of several genes and regulate neurotransmitter and synaptic-related proteins levels, thus influencing brain development and function^{33,97}.

Conclusions

In this paper we provide evidence that by modulating gut microbiota several pathways are affected, consequently delaying AD progression. In 3xTg-AD mice, SLAB51 changed the composition of gut microbiota and its metabolites, positively interfering with inflammatory cytokines, gut hormones concentration and proteolysis, reducing A β load and improving cognitive function, demonstrating a role in the prevention and treatment of AD and supporting the idea of the gut microbiota modulation to counteract A β -mediated AD-type pathogenic processes.

References

1. Cecarini, V. *et al.* Crosstalk between the ubiquitin-proteasome system and autophagy in a human cellular model of Alzheimer's disease. *Biochimica et biophysica acta* **1822**, 1741–1751, doi:10.1016/j.bbadis.2012.07.015 (2012).
2. Zheng, Q., Li, J. & Wang, X. Interplay between the ubiquitin-proteasome system and autophagy in proteinopathies. *International journal of physiology, pathophysiology and pharmacology* **1**, 127–142 (2009).
3. Nilsson, P. *et al.* Abeta secretion and plaque formation depend on autophagy. *Cell reports* **5**, 61–69, doi:10.1016/j.celrep.2013.08.042 (2013).
4. van Tijn, P. *et al.* Mutant ubiquitin decreases amyloid beta plaque formation in a transgenic mouse model of Alzheimer's disease. *Neurochemistry international* **61**, 739–748, doi:10.1016/j.neuint.2012.07.007 (2012).
5. Gomes, S. *et al.* Protective effect of leptin and ghrelin against toxicity induced by amyloid-beta oligomers in a hypothalamic cell line. *Journal of neuroendocrinology* **26**, 176–185, doi:10.1111/jne.12138 (2014).
6. Folch, J. *et al.* The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. *Life sciences*. doi:10.1016/j.lfs.2015.05.002 (2015).
7. Theodoropoulou, A., Metallinos, I. C., Psyrogiannis, A., Vagenakis, G. A. & Kyriazopoulou, V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. *The journal of nutrition, health & aging* **16**, 472–477 (2012).
8. Stoyanova. Ghrelin: A link between ageing, metabolism and neurodegenerative disorders. *Neurobiology of Disease*, 1–12 (2014).

9. Moon, M. *et al.* Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomer-injected mice. *Journal of Alzheimer's disease: JAD* **23**, 147–159, doi:10.3233/JAD-2010-101263 (2011).
10. Niedowicz, D. M. *et al.* Leptin regulates amyloid beta production via the gamma-secretase complex. *Biochimica et biophysica acta* **1832**, 439–444, doi:10.1016/j.bbdis.2012.12.009 (2013).
11. Fewlass, D. C. *et al.* Obesity-related leptin regulates Alzheimer's Abeta. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **18**, 1870–1878, doi:10.1096/fj.04-2572com (2004).
12. Greco, S. J. *et al.* Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimer's disease: JAD* **19**, 1155–1167, doi:10.3233/JAD-2010-1308 (2010).
13. Rigamonti, A. E. *et al.* Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. *The Journal of endocrinology* **175**, R1–5 (2002).
14. Perry, T. *et al.* Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. *Journal of neuroscience research* **72**, 603–612, doi:10.1002/jnr.10611 (2003).
15. Abbas, T., Faivre, E. & Holscher, C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. *Behavioural brain research* **205**, 265–271, doi:10.1016/j.bbr.2009.06.035 (2009).
16. Gault, V. A. & Holscher, C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. *Journal of neurophysiology* **99**, 1590–1595, doi:10.1152/jn.01161.2007 (2008).
17. Faivre, E. & Holscher, C. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. *Alzheimer's research & therapy* **5**, 20, doi:10.1186/alzrt174 (2013).
18. Bhattacharjee, S. & Lukiw, W. J. Alzheimer's disease and the microbiome. *Frontiers in cellular neuroscience* **7**, 153, doi:10.3389/fncel.2013.00153 (2013).
19. Wang, Y. & Kasper, L. H. The role of microbiome in central nervous system disorders. *Brain, behavior, and immunity* **38**, 1–12, doi:10.1016/j.bbi.2013.12.015 (2014).
20. Kang, S. S. *et al.* Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. *Molecular neurodegeneration* **9**, 36, doi:10.1186/1750-1326-9-36 (2014).
21. Tang, M. L. *et al.* Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *The Journal of allergy and clinical immunology* **135**, 737–744 e738, doi:10.1016/j.jaci.2014.11.034 (2015).
22. Penha Filho, R. A. *et al.* Immunomodulatory activity and control of Salmonella Enteritidis colonization in the intestinal tract of chickens by Lactobacillus based probiotic. *Veterinary immunology and immunopathology*, doi:10.1016/j.vetimm.2015.06.006 (2015).
23. Fedorak, R. N. *et al.* The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association* **13**, 928–935 e922, doi:10.1016/j.cgh.2014.10.031 (2015).
24. Rossi, G. *et al.* Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. *PloS one* **9**, e94699, doi:10.1371/journal.pone.0094699 (2014).
25. Talero, E. *et al.* Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. *Inflammatory bowel diseases* **21**, 1027–1037, doi:10.1097/MIB.0000000000000346 (2015).
26. Duncan, S. H. & Flint, H. J. Probiotics and prebiotics and health in ageing populations. *Maturitas* **75**, 44–50, doi:10.1016/j.maturitas.2013.02.004 (2013).
27. Saulnier, D. M. *et al.* The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. *Gut microbes* **4**, 17–27, doi:10.4161/gmic.22973 (2013).
28. von Geldern, G. & Mowry, E. M. The influence of nutritional factors on the prognosis of multiple sclerosis. *Nature reviews. Neurology* **8**, 678–689, doi:10.1038/nrneurol.2012.194 (2012).
29. Camfield, D. A., Owen, L., Scholey, A. B., Pipingas, A. & Stough, C. Dairy constituents and neurocognitive health in ageing. *The British journal of nutrition* **106**, 159–174, doi:10.1017/S0007114511000158 (2011).
30. Douglas-Escobar, M., Elliott, E. & Neu, J. Effect of intestinal microbial ecology on the developing brain. *JAMA pediatrics* **167**, 374–379, doi:10.1001/jamapediatrics.2013.497 (2013).
31. Hsiao, E. Y. *et al.* Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell* **155**, 1451–1463, doi:10.1016/j.cell.2013.11.024 (2013).
32. Davari, S., Talaei, S. A., Alaei, H. & Salami, M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome-gut-brain axis. *Neuroscience* **240**, 287–296, doi:10.1016/j.neuroscience.2013.02.055 (2013).
33. Distrutti, E. *et al.* Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. *PloS one* **9**, e106503, doi:10.1371/journal.pone.0106503 (2014).
34. Vinolo, M. A., Rodrigues, H. G., Nachbar, R. T. & Curi, R. Regulation of inflammation by short chain fatty acids. *Nutrients* **3**, 858–876, doi:10.3390/nu3100858 (2011).
35. Oleskin, A. V. & Shenderov, B. A. Neuromodulatory effects and targets of the SCFAs and gasotransmitters produced by the human symbiotic microbiota. *Microbial ecology in health and disease* **27**, 30971, doi:10.3402/mehd.v27.30971 (2016).
36. Orlowski, M. & Michaud, C. Pituitary multicatalytic proteinase complex. *Specificity of components and aspects of proteolytic activity. Biochemistry* **28**, 9270–9278 (1989).
37. Pfeleiderer, G. & Celliers, P. G. Isolation of an Aminopeptidase from Kidney Particles. *Biochemische Zeitschrift* **339**, 186–189 (1963).
38. Oddo, S. *et al.* Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* **39**, 409–421 (2003).
39. Crawford, J. D., Terry, M. E. & Rourke, G. M. Simplification of drug dosage calculation by application of the surface area principle. *Pediatrics* **5**, 783–790 (1950).
40. Nasuti, C. *et al.* Dopaminergic system modulation, behavioral changes, and oxidative stress after neonatal administration of pyrethroids. *Toxicology* **229**, 194–205, doi:10.1016/j.tox.2006.10.015 (2007).
41. Leger, M. *et al.* Object recognition test in mice. *Nature protocols* **8**, 2531–2537, doi:10.1038/nprot.2013.155 (2013).
42. Nasuti, C. *et al.* Neonatal exposure to permethrin pesticide causes lifelong fear and spatial learning deficits and alters hippocampal morphology of synapses. *Journal of neurodevelopmental disorders* **6**, 7, doi:10.1186/1866-1955-6-7 (2014).
43. Kim, H. Y. *et al.* Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. *Scientific reports* **4**, 7467, doi:10.1038/srep07467 (2014).
44. Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. *Psychopharmacology* **92**, 180–185 (1987).
45. Nasuti, C. *et al.* Effects of early life permethrin exposure on spatial working memory and on monoamine levels in different brain areas of pre-senescent rats. *Toxicology* **303**, 162–168, doi:10.1016/j.tox.2012.09.016 (2013).
46. Bell, E. T. *et al.* Faecal microbiota of cats with insulin-treated diabetes mellitus. *PloS one* **9**, e108729, doi:10.1371/journal.pone.0108729 (2014).
47. McDonald, D. *et al.* An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *The ISME journal* **6**, 610–618, doi:10.1038/ismej.2011.139 (2012).

48. Fiorini, D., Boarelli, M. C., Gabbianelli, R., Ballini, R. & Pacetti, D. A quantitative headspace-solid-phase microextraction-gas chromatography-flame ionization detector method to analyze short chain free fatty acids in rat feces. *Analytical biochemistry* **508**, 12–14, doi:[10.1016/j.ab.2016.05.023](https://doi.org/10.1016/j.ab.2016.05.023) (2016).
49. Paxinos, G. & Franklin, K. B. J. *The mouse brain in stereotaxic coordinates* (Academic Press, 2001).
50. Liu, P. *et al.* Characterization of a Novel Mouse Model of Alzheimer's Disease–Amyloid Pathology and Unique beta-Amyloid Oligomer Profile. *PLoS one* **10**, e0126317, doi:[10.1371/journal.pone.0126317](https://doi.org/10.1371/journal.pone.0126317) (2015).
51. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical biochemistry* **72**, 248–254 (1976).
52. Eleuteri, A. M. *et al.* Isolation and characterization of bovine thymus multicatalytic proteinase complex. *Protein expression and purification* **18**, 160–168, doi:[10.1006/prep.1999.1187](https://doi.org/10.1006/prep.1999.1187) (2000).
53. Tchoupe, J. R., Moreau, T., Gauthier, F. & Bieth, J. G. Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. *Biochimica et biophysica acta* **1076**, 149–151 (1991).
54. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nature methods* **9**, 671–675 (2012).
55. Marchini, C., Angeletti, M., Eleuteri, A. M., Fedeli, A. & Fioretti, E. Aspirin modulates LPS-induced nitric oxide release in rat glial cells. *Neuroscience letters* **381**, 86–91, doi:[10.1016/j.neulet.2005.02.002](https://doi.org/10.1016/j.neulet.2005.02.002) (2005).
56. Evans, S. J. *et al.* Dysregulation of the fibroblast growth factor system in major depression. *Proceedings of the National Academy of Sciences of the United States of America* **101**, 15506–15511, doi:[10.1073/pnas.0406788101](https://doi.org/10.1073/pnas.0406788101) (2004).
57. Bernard, R. *et al.* Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. *Molecular psychiatry* **16**, 634–646, doi:[10.1038/mp.2010.44](https://doi.org/10.1038/mp.2010.44) (2011).
58. Gaughran, F., Payne, J., Sedgwick, P. M., Cotter, D. & Berry, M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. *Brain research bulletin* **70**, 221–227, doi:[10.1016/j.brainresbull.2006.04.008](https://doi.org/10.1016/j.brainresbull.2006.04.008) (2006).
59. Allen-Vercoe, E. *et al.* Anaerostipes hadrum comb. nov., a dominant species within the human colonic microbiota; reclassification of *Eubacterium hadrum* Moore *et al.* 1976. *Anaerobe* **18**, 523–529, doi:[10.1016/j.anaerobe.2012.09.002](https://doi.org/10.1016/j.anaerobe.2012.09.002) (2012).
60. Sanchez-Ramos, J. *et al.* Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. *Neuroscience* **163**, 55–72, doi:[10.1016/j.neuroscience.2009.05.071](https://doi.org/10.1016/j.neuroscience.2009.05.071) (2009).
61. McKinnon, C. & Tabrizi, S. J. The ubiquitin-proteasome system in neurodegeneration. *Antioxidants & redox signaling* **21**, 2302–2321, doi:[10.1089/ars.2013.5802](https://doi.org/10.1089/ars.2013.5802) (2014).
62. Hook, G., Yu, J., Toneff, T., Kindy, M. & Hook, V. Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. *Journal of Alzheimer's disease: JAD* **41**, 129–149, doi:[10.3233/JAD-131370](https://doi.org/10.3233/JAD-131370) (2014).
63. Klein, D. M., Felsenstein, K. M. & Brenneman, D. E. Cathepsins B and L differentially regulate amyloid precursor protein processing. *The Journal of pharmacology and experimental therapeutics* **328**, 813–821, doi:[10.1124/jpet.108.147082](https://doi.org/10.1124/jpet.108.147082) (2009).
64. Kang, R., Zeh, H. J., Lotze, M. T. & Tang, D. The Beclin 1 network regulates autophagy and apoptosis. *Cell death and differentiation* **18**, 571–580, doi:[10.1038/cdd.2010.191](https://doi.org/10.1038/cdd.2010.191) (2011).
65. Klionsky, D. J. *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* **8**, 445–544 (2012).
66. Bjorkoy, G. *et al.* Monitoring autophagic degradation of p62/SQSTM1. *Methods in enzymology* **452**, 181–197, doi:[10.1016/S0076-6879\(08\)03612-4](https://doi.org/10.1016/S0076-6879(08)03612-4) (2009).
67. Sultana, R., Perluigi, M. & Butterfield, D. A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. *Acta neuropathologica* **118**, 131–150, doi:[10.1007/s00401-009-0517-0](https://doi.org/10.1007/s00401-009-0517-0) (2009).
68. Takashima, A. A-beta, tau, and dementia. *Journal of Alzheimer's disease: JAD* **17**, 729–736, doi:[10.3233/JAD-2009-1090](https://doi.org/10.3233/JAD-2009-1090) (2009).
69. Bercik, P., Collins, S. M. & Verdu, E. F. Microbes and the gut-brain axis. *Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society* **24**, 405–413, doi:[10.1111/j.1365-2982.2012.01906.x](https://doi.org/10.1111/j.1365-2982.2012.01906.x) (2012).
70. Distrutti, E., Cipriani, S., Mencarelli, A., Renga, B. & Fiorucci, S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. *PLoS one* **8**, e63893, doi:[10.1371/journal.pone.0063893](https://doi.org/10.1371/journal.pone.0063893) (2013).
71. Khokhlova, E. V. *et al.* Anti-inflammatory properties of intestinal Bifidobacterium strains isolated from healthy infants. *Microbiology and immunology* **56**, 27–39, doi:[10.1111/j.1348-0421.2011.00398.x](https://doi.org/10.1111/j.1348-0421.2011.00398.x) (2012).
72. Okada, Y. *et al.* Anti-inflammatory effects of the genus Bifidobacterium on macrophages by modification of phospho-I kappaB and SOCS gene expression. *International journal of experimental pathology* **90**, 131–140, doi:[10.1111/j.1365-2613.2008.00632.x](https://doi.org/10.1111/j.1365-2613.2008.00632.x) (2009).
73. Hamza, E., Kittl, S. & Kuhnert, P. Temporal induction of pro-inflammatory and regulatory cytokines in human peripheral blood mononuclear cells by Campylobacter jejuni and Campylobacter coli. *PLoS one* **12**, e0171350, doi:[10.1371/journal.pone.0171350](https://doi.org/10.1371/journal.pone.0171350) (2017).
74. Barjesteh, N. *et al.* Induction of chicken cytokine responses *in vivo* and *in vitro* by lipooligosaccharide of Campylobacter jejuni HS-10. *Veterinary microbiology* **164**, 122–130, doi:[10.1016/j.vetmic.2013.02.002](https://doi.org/10.1016/j.vetmic.2013.02.002) (2013).
75. Barrett, E., Ross, R. P., O'Toole, P. W., Fitzgerald, G. F. & Stanton, C. gamma-Aminobutyric acid production by culturable bacteria from the human intestine. *Journal of applied microbiology* **113**, 411–417, doi:[10.1111/j.1365-2672.2012.05344.x](https://doi.org/10.1111/j.1365-2672.2012.05344.x) (2012).
76. Lyte, M., Varcoe, J. J. & Bailey, M. T. Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. *Physiology & behavior* **65**, 63–68 (1998).
77. Kountouras, J. *et al.* Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. *Journal of neurology* **256**, 758–767, doi:[10.1007/s00415-009-5011-z](https://doi.org/10.1007/s00415-009-5011-z) (2009).
78. Irving, A. J. & Harvey, J. Leptin regulation of hippocampal synaptic function in health and disease. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* **369**, 20130155, doi:[10.1098/rstb.2013.0155](https://doi.org/10.1098/rstb.2013.0155) (2014).
79. Hebda-Bauer, E. K. *et al.* 3xTg-AD mice exhibit an activated central stress axis during early-stage pathology. *Journal of Alzheimer's disease: JAD* **33**, 407–422, doi:[10.3233/JAD-2012-121438](https://doi.org/10.3233/JAD-2012-121438) (2013).
80. Malcher-Lopes, R. *et al.* Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **26**, 6643–6650, doi:[10.1523/JNEUROSCI.5126-05.2006](https://doi.org/10.1523/JNEUROSCI.5126-05.2006) (2006).
81. Holscher, C. The incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **10**, S47–S54, doi:[10.1016/j.jalz.2013.12.009](https://doi.org/10.1016/j.jalz.2013.12.009) (2014).
82. Cox, M. A. *et al.* Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. *World journal of gastroenterology* **15**, 5549–5557 (2009).
83. Russo, R. *et al.* Gut-brain axis: Role of lipids in the regulation of inflammation, pain and CNS diseases. *Current medicinal chemistry*, doi:[10.2174/0929867324666170216113756](https://doi.org/10.2174/0929867324666170216113756) (2017).
84. Lei, E., Vacy, K. & Boon, W. C. Fatty acids and their therapeutic potential in neurological disorders. *Neurochemistry international* **95**, 75–84, doi:[10.1016/j.neuint.2016.02.014](https://doi.org/10.1016/j.neuint.2016.02.014) (2016).
85. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Perez-Otano, I. & Garcia-Osta, A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. *Hippocampus* **22**, 1040–1050, doi:[10.1002/hipo.20883](https://doi.org/10.1002/hipo.20883) (2012).

86. Frost, G. *et al.* The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nature communications* **5**, 3611, doi:[10.1038/ncomms4611](https://doi.org/10.1038/ncomms4611) (2014).
87. Ohsawa, K., Uchida, N., Ohki, K., Nakamura, Y. & Yokogoshi, H. Lactobacillus helveticus-fermented milk improves learning and memory in mice. *Nutritional neuroscience* **18**, 232–240, doi:[10.1179/1476830514Y.0000000122](https://doi.org/10.1179/1476830514Y.0000000122) (2015).
88. Keller, J. N., Hanni, K. B. & Markesbery, W. R. Impaired proteasome function in Alzheimer's disease. *Journal of neurochemistry* **75**, 436–439 (2000).
89. Kitamura, Y. *et al.* Changes of p53 in the brains of patients with Alzheimer's disease. *Biochemical and biophysical research communications* **232**, 418–421, doi:[10.1006/bbrc.1997.6301](https://doi.org/10.1006/bbrc.1997.6301) (1997).
90. Ohya, Y. *et al.* Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **19**, 255–257, doi:[10.1096/fj.04-2637fje](https://doi.org/10.1096/fj.04-2637fje) (2005).
91. de la Monte, S. M., Sohn, Y. K. & Wands, J. R. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. *Journal of the neurological sciences* **152**, 73–83 (1997).
92. Hooper, C. *et al.* p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. *Neuroscience letters* **418**, 34–37, doi:[10.1016/j.neulet.2007.03.026](https://doi.org/10.1016/j.neulet.2007.03.026) (2007).
93. Cecarini, V. *et al.* Effects of Ghrelin on the Proteolytic Pathways of Alzheimer's Disease Neuronal Cells. *Molecular neurobiology*. doi:[10.1007/s12035-015-9227-x](https://doi.org/10.1007/s12035-015-9227-x) (2015).
94. Ulloa, F. & Marti, E. Wnt won the war: antagonistic role of Wnt over Shh controls dorso-ventral patterning of the vertebrate neural tube. *Developmental dynamics: an official publication of the American Association of Anatomists* **239**, 69–76, doi:[10.1002/dvdy.22058](https://doi.org/10.1002/dvdy.22058) (2010).
95. Aurbach, E. L. *et al.* Fibroblast growth factor 9 is a novel modulator of negative affect. *Proceedings of the National Academy of Sciences of the United States of America* **112**, 11953–11958, doi:[10.1073/pnas.1510456112](https://doi.org/10.1073/pnas.1510456112) (2015).
96. Nakamura, S. *et al.* Fibroblast growth factor (FGF)-9 immunoreactivity in senile plaques. *Brain research* **814**, 222–225 (1998).
97. Diaz Heijtz, R. *et al.* Normal gut microbiota modulates brain development and behavior. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 3047–3052, doi:[10.1073/pnas.1010529108](https://doi.org/10.1073/pnas.1010529108) (2011).

Acknowledgements

University of Camerino funds supported this study.

Author Contributions

Conceptualization, E.A.M.; Methodology, E.A.M. and L.B.; Investigation, B.L., R.G., B.S., S.S., N.C., S.J., F.D., and B.M.C.; Formal analysis and Visualization, B.L. and C.V.; Writing—Original Draft, B.L. and C.V.; Writing—Review & Editing, B.L. and C.V.; Funding Acquisition, E.A.M.; Resources, E.A.M.; Supervision, E.A.M. and R.G. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at doi:[10.1038/s41598-017-02587-2](https://doi.org/10.1038/s41598-017-02587-2)

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017